miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms
- PMID: 34291333
- DOI: 10.1007/s00277-021-04598-6
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms
References
-
- Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://doi.org/10.1182/blood-2016-08-733196 - DOI - PubMed - PMC
-
- Cazzola M (2020) Myelodysplastic syndromes. N Engl J Med 383:1358–1374. https://doi.org/10.1056/NEJMra1904794 - DOI - PubMed
-
- Patnaik MM, Tefferi A (2020) Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol 95:97–115. https://doi.org/10.1002/ajh.25684 - DOI - PubMed
-
- Gordon JE, Wong JJ, Rasko JE (2013) MicroRNAs in myeloid malignancies. Br J Haematol 162:162–176. https://doi.org/10.1111/bjh.12364 - DOI - PubMed
-
- Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314. https://doi.org/10.1146/annurev-pathol-012513-104715 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
